Off-market insider buying at Biomark Diagnostics (C:BUX)

Rashid Bux, a Director, acquired 1,032,261 Common Shares on an indirect ownership basis for registered holder BUX INVESTMENT LTD at a price of $0.250 through a prospectus or prospectus exempt offering on December 29th, 2023. The insider also acquired 1,032,261 Warrants with an exercise price of $0.450 for three years. This represents a $258,065 investment into the company's shares and an account share holdings change of 30.2%.

Biomark Diagnostics is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.

BioMark Diagnostics Inc. is a liquid biopsy company. The Company is developing a molecular diagnostics technology platform, which leverages the power of metabolomics and machine learning algorithms to bring new cancer diagnostics to market and improve cancer prognosis by allowing physicians to detect carcinomas in the pre-symptomatic stages. The technology can also be used for measuring response to treatment and potentially for serial monitoring of cancer survivors. Its cancer diagnostics technology platform leverages Omics and machine learning with a focus on cancers that are hard to detect and treat. Its liquid biopsy assay detects Spermidine/spermine N-acetyltransferase 1 (SSAT1). SSAT1 is an enzyme with elevated levels in numerous cancers. It has also developed a new high powered liquid biopsy metabolic panel assay. The new metabolic assay is instrumental for early-stage diagnosis of lung cancer. The liquid biopsy metabolic panel has demonstrated clinical detections.